The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://lorizhxz226536.wikibyby.com/2014393/glp_3_retatrutide_a_comparative_analysis